$135.90
N/A
Last update: Nov 9, 4:00 PM
Protagonist Therapeutics Inc
PTGXNASDAQ
Protagonist Therapeutics (PTGX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $2.64 | $1.84 | $-0.65 | $-0.54 |
| Actual | $3.07 | $2.29 | $0.05 | $-0.69 |
| Surprise | +16.3% | +24.5% | +107.7% | -27.8% |
| Revenue | ||||
| Estimate | $246.5M | $213.1M | $14.0M | $14.3M |
| Actual | $274.4M | $213.5M | $56.4M | $7.4M |
| Surprise | +11.3% | +0.16% | +302.1% | -47.9% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.10 | $-0.16 | $-0.52 | $-0.61 |
| Revenue | ||||
| Consensus | $104.8M | $54.0M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $3.07 | $2.64 | 16.3 % |
| Q2 | Aug 5, 2026 | $2.29 | $1.84 | 24.5 % |
| Q1 | May 5, 2026 | $0.05 | $-0.65 | 107.7 % |
| Q4 | Feb 25, 2026 | $-0.69 | $-0.54 | -27.8 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $274.41M | $246.46M | 11.3 % |
| Q2 | Aug 5, 2026 | $213.48M | $213.13M | 0.16 % |
| Q1 | May 5, 2026 | $56.37M | $14.02M | 302.1 % |
| Q4 | Feb 25, 2026 | $7.44M | $14.27M | -47.9 % |
